Wednesday, January 18, 2012
abstract: Extraperitoneal Metastases From Recurrent Ovarian Cancer (stage 111 ovarian cancer patients)
International Journal of Gynecological Cancer:
January 2012 - Volume 22 - Issue 1 - p 43–46
doi: 10.1097/IGC.0b013e31823532ce
Ovarian Cancer
Extraperitoneal Metastases From Recurrent Ovarian Cancer
Robinson, William R. MD*; Beyer, Julie RN, BSN†; Griffin, Stephen MD†; Kanjanavaikoon, Paiyarut MD‡
Abstract
Objectives: To identify patterns of metastasis in
patients with recurrent ovarian cancer. The influence of the route of
chemotherapy administration and sequence of agents on those patterns is
also examined.
Results: Thirty-five subjects developed
extraperitoneal recurrent ovarian cancer, with 26 subjects (74%) after
IP treatment, and 9 subjects (26%) after IV treatment. Of these
extraperitoneal recurrences, 26 were in the thoracic/pulmonary cavity, 7
were within the central nervous system (CNS), and 2 were in the
cutaneous tissues. The CNS and cutaneous lesions were secondary
recurrences, and all occurred in subjects who had initially received IP
cisplatin/paclitaxel followed by IV BEV for recurrent disease.
Conclusions: Extraperitoneal recurrences were more
common in women treated with IP chemotherapy for ovarian cancer.
Specifically, women treated with IV BEV as secondary therapy after IP
were at particularly high risk of extraperitoneal metastases, including
in the CNS and cutaneous tissues. Physicians should be aware of the
possibility of unusual metastases after the combination of IP
chemotherapy and BEV, and future prospective studies of this population
should carefully evaluate recurrence site patterns.
Firefox - Why is the Internet on strike today?
Today, Mozilla is joining the virtual strike against Internet censorship – along with others like Wikipedia and Google – to raise awareness of US Congress legislation that could fundamentally alter the Internet we know and love.
This harmful legislation, called the Stop Online Piracy Act (SOPA) in the House and the PROTECT IP Act (PIPA) in the Senate, will be voted on as early as January 24th in the Senate.
If you live in the US, there's still time to help stop these bills from becoming law. Please visit mozilla.org/sopa for information on the bill, and on ways you can reach out to your senators.
What makes this legislation so bad? Here's how it would change the Web:......
The Oncologist: Immunogenicity of an Inactivated Monovalent 2009 Influenza A (H1N1) Vaccine in Patients Who Have Cancer (prospective single site study + 2 related articles))
Blogger's Note: reminder - full access requires subscription ($$$); note also related articles
Abstract
Background. The immune response of patients who have cancer, who may be receiving immunosuppressive therapy, is generally considered to be decreased. This study aimed to evaluate the immune response of cancer patients to the 2009 influenza A (H1N1) vaccine.
- COMMENTARY
- Vaccination of Oncology Patients: An Effective Tool and an Opportunity Not to Be Missed
- Camille N. Kotton, Mark C. Poznansky
- Oncologist published 12 January 2012, 10.1634/theoncologist.2011-0383
http://theoncologist.alphamedpress.org/cgi/reprint/theoncologist.2011-0383v1
.......................................................................................
- OUTCOMES RESEARCH: CASE REPORT
- Immunogenicity of an Inactivated Monovalent 2009 Influenza A (H1N1) Vaccine in Patients Who Have Cancer
- Yiqing Xu, Nanda Methuku, Praveena Coimbatore, Theresa Fitzgerald, Yiwu Huang, Ying-Yi Xiao, Murali Pagala, Shachi Gupta, William Solomon, Philip Rubin, John Treanor, Alan Astrow, Howard Minkoff, Jay S. Cooper
- Oncologist published 12 January 2012, 10.1634/theoncologist.2011-0220
http://theoncologist.alphamedpress.org/cgi/content/abstract/theoncologist.2011-0220v1
- OUTCOMES RESEARCH: CASE REPORT
open access: Thoracic metastasis in advanced ovarian cancer: comparison between computed tomography and video-assisted thoracic surgery
| Blogger's Note: click on 'pdf' to access full paper | |||||||||||||||||||||
| Objective: To determine which computed tomography (CT) imaging features predict pleural malignancy in patients with advanced epithelial ovarian carcinoma (EOC) using video-assisted thoracic surgery (VATS), pathology, and cytology findings as the reference standard. | |||||||||||||||||||||
A Risk-Adapted Strategy of Adjuvant Paclitaxel/Carboplatin in Early-Stage Ovarian Cancer: Time-Dependent Effect of 4 versus 6 Cycles on Outcome.
Abstract
Objective:We investigated the efficacy of risk-adapted adjuvant paclitaxel/carboplatin chemotherapy in early-stage ovarian carcinoma.
Methods: Fifty-three patients were treated according to the risk of relapse: patients with stages IA or IB or with grade 1 (low risk) received 4 cycles of paclitaxel and carboplatin; patients with IC/IIA and grade 2 or 3 (high risk) received 6 cycles of chemotherapy. The outcome was compared with that of 95 patients who were all treated with 4 cycles.
Results: Median follow-up was 88, 113 and 42 months for the whole cohort, non-risk-adapted and risk-adapted treatment, respectively.
Five-year relapse-free and disease-specific survival was 86 and 93% for the whole population, 96 and 97% for low-risk and 81 and 91% for high-risk patients.
Risk classification was the only significant prognostic factor for relapse-free (p = 0.011) and disease-specific survival (p = 0.039). Among high-risk patients, the administration of 6 cycles was associated with a significantly lower relapse rate after censoring events, which occurred beyond 2 years (3 vs. 18%; p = 0.013), but this difference was diminished at 5 years (23 vs. 25%; p = 0.797).
Conclusions: Six cycles of chemotherapy reduced the risk of relapse within 2 years, but the benefit from two additional cycles beyond this time is questionable.
short abstract: Gynecological cancer: True progress in ovarian cancer or just the tip of the iceberg?
Blogger's Note: requires subscription to view full text ($$$)
Gynecological cancer: True progress in ovarian cancer or just the tip of the iceberg?
"Abstract
Development
of malignant ascites is common in patients with ovarian cancer, and few
therapeutic options exist for women with ascites whose tumors become
resistant to chemotherapy. Furthermore, in such patients symptom
palliation options are limited, and the few available treatments are
unpleasant and can result in the need for paracentesis."
Concurrent Endometrial Intraepithelial Carcinoma (EIC) and Serous Ovarian Cancer: Can EIC Be Seen as the Precursor Lesion?
OBJECTIVE:
The pathogenesis of serous ovarian carcinoma (SOC) is still unknown. Recently, endometrial intraepithelial carcinoma (EIC) was proposed to be the precursor lesion of SOC. This study examines the model of EIC as precursor for SOC.
CONCLUSION:
This study provides a first indication of EIC as possible precursor lesion for SOC. This finding could have major clinical implications for future ovarian cancer management and underscores EIC as a possible target for early SOC detection and prevention.The Oncologist: commentary + link to original paper - Calcium and Magnesium Prophylaxis for Oxaliplatin-Related (taxanes) Neurotoxicity: Is It a Trade-off Between Drug Efficacy and Toxicity?
1) link to commentary:
Calcium and Magnesium Prophylaxis for Oxaliplatin-Related Neurotoxicity: Is It a Trade-off Between Drug Efficacy and Toxicity?
"In this context, a large international academic trial involving several U.S. and European oncological centers—the Chemotherapy-Induced Peripheral Neuropathy Outcome Measures Standardization (CI-PERINOMS) study[16]—recently completed the enrollment of >280 patients with CIPN who were examined with an extended series of scales and questionnaires to assess their reliability and validity, a critical step in the search for the optimal method to detect and describe its features in daily practice and in clinical trials. In fact, until reliable, valid, reproducible, and responsive methods are used to properly assess CIPN, any effort to establish an effective neuroprotection treatment will be unrealistic."
2) link to original paper:
Calcium and Magnesium Prophylaxis for Oxaliplatin-Related Neurotoxicity: Is It a Trade-off Between Drug Efficacy and Toxicity?
"......Furthermore, there is a lack of standardization in timing of assessment of neurotoxicity and inadequate assessment of long-term neurotoxicity related to oxaliplatin between studies investigating Ca/Mg prophylaxis. Also, because of the initial concerns raised by the IDMC examining the CONCePT trial, many of the major trials were terminated early and are thus underpowered. The NCCTG has initiated another prospective randomized, double-blinded trial aimed at addressing these issues." (safety)
Palliative Care in Advanced Cancer Patients: How and When? The Oncologist
Blogger's Note: requires subscription ($$$) to view full text
End Piracy, Not Liberty – Google (petition)
Millions of Americans oppose SOPA and PIPA because these bills would censor the Internet and slow economic growth in the U.S.
Two bills before Congress, known as the Protect IP Act (PIPA) in the Senate and the Stop Online Piracy Act (SOPA) in the House, would censor the Web and impose harmful regulations on American business. Millions of Internet users and entrepreneurs already oppose SOPA and PIPA.The Senate will begin voting on January 24th. Please let them know how you feel. Sign this petition urging Congress to vote NO on PIPA and SOPA before it is too late.
Subscribe to:
Posts
(
Atom
)
Posts
